Pharma Focus America

Johnson & Johnson to Acquire Proteologix, Inc.

Friday, May 17, 2024

Proteologix, Inc., a biotechnology company specializing in bispecific antibodies for immune-mediated diseases, has announced its acquisition by Johnson & Johnson for $850 million in cash, with the potential for additional milestone payments.

Among Proteologix's notable assets are PX128, a bispecific antibody targeting IL-13 and TSLP, set to enter phase 1 development for moderate to severe atopic dermatitis (AD) and asthma, and PX130, targeting IL-13 and IL-22, currently in preclinical development for moderate to severe AD. By addressing multiple pathways in AD and asthma, both PX128 and PX130 aim to offer enhanced efficacy and potential remission.

PX128 targets IL-13-mediated Th2 skin inflammation and TSLP, while PX130 inhibits IL-13 and IL-22, aiming to restore the skin barrier and prevent inflammation from environmental triggers. These drugs are designed for infrequent dosing intervals, prioritizing patient convenience.

Proteologix, expressed the company's commitment to advancing immunology and inflammation diseases through specialized, multi-functional antibody drugs. The acquisition by Johnson & Johnson is seen as an opportunity to expedite the development of lead programs in atopic dermatitis, asthma, and other immune-mediated diseases.

Beyond PX128 and PX130, Johnson & Johnson stands to gain access to Proteologix's other bispecific antibody programs with potential applications across various diseases.

The completion of the transaction is contingent upon customary closing conditions. Proteologix was advised by Centerview Partners LLC as the exclusive financial advisor and Goodwin Procter as legal counsel.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024